Flow NeuroscienceFDA-approved (PMA) and CE-marked tDCS headset for depression (prescription-only in the US)Evidence-based assessment
Flow Neuroscience review
Updated 2026-09-30
6.7
/ 10
Not EEG — clinical tDCS for depression, with the strongest regulatory and trial backing in this list.Reference clinical tDCS — for users with major depression who want a take-home device with regulatory and trial backing.
Flow Neuroscience is a Swedish-built tDCS (transcranial direct-current stimulation) headset paired with a structured cognitive-behavioural programme app, indicated for major depression. CE-marked as a Class IIa medical device in the EU and prescribed within the UK NHS in some pathways; in the US it received FDA premarket approval (PMA P230024, 8 December 2025) for moderate-to-severe major depression in adults who are not treatment-resistant, and has been available by prescription only (in person or via telehealth) since September 2026. Not EEG — Flow stimulates, not measures — but lives in the consumer brain-training buying conversation. The clinical reference for take-home tDCS in this list (its main trial was funded by Flow).
How we tested: Evidence-based assessment — scored from Flow Neuroscience product documentation, the published Flow tDCS trial record and independent 2026 reviews. Not hands-on tested by ONDA. Included as the clinical tDCS reference point in this category.
tDCS — transcranial direct-current stimulation over the dorsolateral prefrontal cortex (the kind used in clinical trials). Disclosed stimulation parameters (2 mA, 30-minute sessions); CE-marked Class IIa medical device.
Training programmes and content
8.0
Structured 8-week behavioural-therapy programme paired with stimulation sessions — the strongest content scaffolding in this list because it is built around a clinical protocol.
Insights and analysis quality
6.0
Mood and adherence tracking against validated scales (PHQ-9). Less granular than EEG headsets — Flow tracks symptoms, not brain signal.
Comfort and wearability
7.0
Rigid headset; 30-minute seated sessions. Some users report a transient scalp tingle or itch during stimulation — well-documented and reversible.
App and integration UX
7.5
Polished app with daily check-ins and adherence tracking.
Open data and developer access
4.0
Closed platform — clinical programme design, not a developer environment.
Value
5.5
£399 (~$499) hardware plus monthly therapy-app subscription in the UK. NHS routes available in some UK regions reduce out-of-pocket cost. US price not yet published.
Pros
+FDA premarket approval (Dec 2025) plus CE-marked Class IIa medical device — the strongest regulatory backing in this list
+Real randomised-trial evidence for depression (including a fully remote randomised sham-controlled trial published in Nature Medicine (Woodham 2024))
+Prescribed within parts of the UK NHS as a depression-pathway option
Cons
−Not EEG — Flow stimulates rather than measures, included for editorial completeness
−Indication restricted to major depression; prescription-only in the US
−Monthly subscription on top of the hardware cost
−Closed platform — no developer access or raw data
Price: $499 £399 UK device + monthly therapy-app subscription; US: prescription-only, price not yet published (as of 2026-05-21)
Where it leads
Flow Neuroscience is the clinical reference for take-home tDCS — the most regulated, most trial-backed device in this list, though its main randomised trial (Woodham 2024) was funded by Flow. CE-marked as a Class IIa medical device in the EU, granted FDA premarket approval (PMA P230024, 8 December 2025) for moderate-to-severe major depression in adults (not treatment-resistant), paired with a structured eight-week behavioural-therapy programme, and prescribed within parts of the UK NHS as a depression-pathway option. Since September 2026 it has been available across the US by prescription only, after an in-person or telehealth evaluation. The published randomised-trial evidence for tDCS in major depression is real and growing; Flow’s contribution is packaging that into a take-home protocol patients actually complete.
What are the downsides of Flow Neuroscience?
It is not an EEG headset. Flow stimulates the dorsolateral prefrontal cortex with 2 mA of direct current; it does not measure brain activity. Indication is restricted to major depression — for general focus, meditation or sleep, Flow is the wrong tool. The platform is closed, the price includes a monthly therapy-app subscription on top of the hardware, and outside the UK NHS pathways the full cost is out-of-pocket. In the US, Flow has not yet published a price or an insurance pathway.
Who should buy Flow Neuroscience?
Choose Flow Neuroscience if you have major depression and a clinician open to discussing it as a take-home option — in the US it requires a prescription, and it is a treatment to use under clinical guidance, not a replacement for care. For general brain training, meditation feedback or sleep tracking, this is the wrong category — Muse S Athena and the EEG-based devices are the right shape. Flow is included here as the clinical reference for what regulated, trial-backed brain-targeted hardware looks like.
Background reading
Background on the brain systems behind mood and attention. Flow stimulates the brain with a weak current; it does not record EEG.
No. Flow Neuroscience is a tDCS headset: it stimulates the brain with direct current rather than measuring brain activity. It is indicated for major depression, CE-marked as a Class IIa medical device in the EU, FDA-approved in the US (prescription-only), and paired with a structured cognitive-behavioural programme app.
How much does Flow Neuroscience cost?
In the UK, Flow costs £399 (about $499) for the device, plus a monthly subscription for the therapy app. In the US it is prescription-only and Flow has not yet published a price. That subscription covers the integrated 8-week behavioural-therapy programme. Budget for both, because the ongoing app fee sits on top of the hardware price.
Does Flow Neuroscience work for depression?
Flow has real randomised-trial evidence for depression, including a fully remote randomised sham-controlled trial published in Nature Medicine (Woodham 2024), it is prescribed within parts of the UK NHS as a depression-pathway option, and in December 2025 the FDA approved it for moderate-to-severe major depression in adults. That gives it the strongest regulatory and trial backing in its category, though its indication is restricted to major depression.
Who is Flow Neuroscience best for?
Flow is best for people with major depression who want a take-home device with regulatory and trial backing. It is a poor fit for general brain training or tinkering: the platform is closed, with no developer access or raw data, and it is not indicated for anything beyond depression.
